Denali Therapeutics Inc. (DNLI) Stock
DNLI Key Statistics
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
CEO: Ryan J. Watts. Company website
DNLI — Frequently Asked Questions
What is the DNLI stock price today?
Denali Therapeutics Inc. (DNLI) trades at $19.73, down 0.60% on the day, as of Nov 12, 2026 09:30 UTC.
What is Denali Therapeutics Inc.'s market cap?
Denali Therapeutics Inc. has a market capitalisation of $3.15B, calculated from the live DNLI share price and shares outstanding.
What is the P/E ratio of DNLI?
DNLI has no meaningful price-to-earnings ratio: Denali Therapeutics Inc. lost $1.73 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Denali Therapeutics Inc. make?
Denali Therapeutics Inc. generated revenue of $21.38M over the trailing twelve months, which puts the stock at 147.50 times sales.
What is the 52-week range for DNLI?
DNLI has traded between $13.75 and $27.30 over the past 52 weeks, and the last price is 27.7% below that high.
Is Denali Therapeutics Inc. profitable?
No. Denali Therapeutics Inc. is loss-making, with a net margin of -1,470.50% over the trailing twelve months.
What is the analyst price target for DNLI?
Wall Street analysts rate DNLI Buy, with an average price target of $33.67, 70.7% above the current price.
What sector is Denali Therapeutics Inc. in?
Denali Therapeutics Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Denali Therapeutics Inc.?
Ryan J. Watts is the chief executive of Denali Therapeutics Inc., which employs 503 people.
Where can I track DNLI in real time?
QFI Terminal shows DNLI with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See DNLI live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open DNLI in Terminal See plans